Hong Kong Cornerstone Robotics has announced the successful closing of an oversubscribed financing round of approximately US$200 million. The round was anchored by the Hong Kong Investment Corporation (HKIC) the government’s strategic investment arm and included participation from leading venture capital firms such as Qiming Venture Partners, Gaorong Ventures and BridgeOne Capital.

Founded in 2019 and headquartered in Hong Kong Science and Technology Park, Cornerstone Robotics operates a major manufacturing facility in Shenzhen with more than 200 engineers. The company’s flagship product, the Sentire Endoscopic Surgical System, has been approved by China’s National Medical Products Administration (NMPA) and is in clinical use in China, Hong Kong and parts of Europe.

The company said the new funding will accelerate its global commercialisation roadmap. Key priorities include scaling production capacity, advancing regulatory registrations in additional markets, expanding hospital deployments beyond tier-1 cities in China, and developing next-generation robotic modules for other surgical specialties.

For Hong Kong, the investment represents a milestone in its strategy to become a hub for deep tech and medical-device innovation. HKIC’s participation demonstrates institutional confidence in Cornerstone’s ability to innovate and succeed globally. CEO and founder Professor Samuel Au Kwok-wai described the round as “a recognition of our technology, ecosystem readiness and global ambition.”

Observers say the surgical-robotics market remains highly competitive with major international players already established but the backing of a local “unicorn” start-up signals greater diversification of innovation ecosystems in Asia. Execution will now hinge on smooth hospital integration, regulatory coverage in more jurisdictions and delivering on affordability and scalability.